Results 21 to 30 of about 181,578 (308)

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma [PDF]

Current Treatment Options in Oncology, 2022
Opinion statementThe therapeutic armamentarium has significantly expanded since the approval of various CD19-targeting chimeric antigen receptor T cell (CAR-T) therapies in non-Hodgkin lymphoma (NHL). These CAR-Ts are patient-specific and require a complex, resource, and time-consuming process.
Arushi Khurana, Yi Lin
openaire   +2 more sources

Rejection of Experimental Hodgkins Lymphoma by T-cells Engineered with a CD19 Chimeric Antigen Receptor [PDF]

, 2012
T cells engineered to express chimeric receptors combining an external antibody binding domain with the CD3ζ T cell receptor (TCR) internal domain for triggering cell activation are being used for immunotherapeutic targeting of tumour cells in a non-HLA ...
Cheadle, Eleanor, Crawford, Dorothy, Gilham, David, Johannessen, Ingolfur, Swanson, Anna, Talbot, Simon   +5 more
core   +1 more source

Engineering and Design of Chimeric Antigen Receptors [PDF]

Molecular Therapy - Methods & Clinical Development, 2019
T cells engineered with chimeric antigen receptors (CARs) have emerged as a potent new class of therapeutics for cancer, based on their remarkable potency in blood cancers. Since the first clinical reports of their efficacy emerged 7 years ago, investigators have focused on the mechanisms and properties that make CARs effective or toxic, and their ...
Sonia Guedan, Hugo Calderon, Avery D. Posey, Jr., Marcela V. Maus   +3 more
openaire   +3 more sources

Chimeric antigen receptor T cell

Indian Journal of Pharmacology, 2022
During present decade, targeted drug therapy has been the epitome for treatment of cancer. Drugs like Imatinib, a tyrosine kinase receptor inhibitor and Trastuzumab, an human epidermal growth factor receptor-2/neu inhibitor, has been developed and accepted widely for management of chronic myeloid leukaemia and breast cancer ...
Singh, Surjit, Khasbage, Sameer, Kaur, Rimple Jeet, Sidhu, Jaspreet Kaur, Bhandari, Bharti   +4 more
openaire   +2 more sources

Global Manufacturing of CAR T Cell Therapy

Molecular Therapy: Methods & Clinical Development, 2017
Immunotherapy using chimeric antigen receptor-modified T cells has demonstrated high response rates in patients with B cell malignancies, and chimeric antigen receptor T cell therapy is now being investigated in several hematologic and solid tumor types.
Bruce L. Levine, James Miskin, Keith Wonnacott, Christopher Keir   +3 more
doaj   +1 more source

CAR-T Therapy in Lymphoma Patients With Coexisting Cardiomyopathy or Cardiac Lymphomatous Involvement

JACC: Case Reports, 2023
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the management of aggressive hematologic malignancies. However, its role in patients with lymphoma and cardiac metastasis or cardiomyopathy remains undefined due to potentially life ...
Choon Ta Ng, MBBS, Hilda M. Gonzalez Bonilla, MD, Ian Chang, MD, M. Tun Aung, MD, Jennifer J. Gile, MD, Naveen L. Pereira, MD, Jose C. Villasboas Bisneto, MD, Patrick B. Johnston, MD, Hector R. Villarraga, MD, Martin G. Rodriguez-Porcel, MD, Grace Lin, MD, Yi Lin, MD, PhD, Joerg Herrmann, MD   +12 more
doaj   +1 more source

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing [PDF]

, 2019
BACKGROUND: Chimeric antigen receptor (CAR)-based T cell therapy is in early clinical trials to target the neuroectodermal tumor, neuroblastoma. No preclinical or clinical efficacy data are available for retinoblastoma to date.
Andersch, Lena, Eggert, Angelika, Flemmig, Carina, Grunewald, Laura, Henssen, Anton, Jensen, Michael C., Joussen, Antonia, Klaus, Anika, Künkele, Annette, Radke, Josefine, Rossig, Claudia, Schulte, Johannes H., Schumann, Elisa, Schwiebert, Silke, Winkler, Annika, Zirngibl, Felix   +15 more
core   +2 more sources

Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report

Journal of Medical Case Reports, 2022
Background Multiple myeloma remains incurable despite treatment advancements over the last 20 years. LCAR-B38M Cells in Treating Relapsed/Refractory Multiple Myeloma was a phase 1, first-in-human, investigator-initiated study in relapsed/refractory ...
Bai-Yan Wang, Wan-Hong Zhao, Yin-Xia Chen, Xing-Mei Cao, Yun Yang, Yi-Lin Zhang, Fang-Xia Wang, Peng-Yu Zhang, Bo Lei, Liu-Fang Gu, Jian-Li Wang, Ju Bai, Yan Xu, Xu-Geng Wang, Rui-Li Zhang, Li-Li Wei, Qiu-Chuan Zhuang, Frank Fan, Wang-Gang Zhang, Ai-Li He, Jie Liu   +20 more
doaj   +1 more source

Combinatorial functions of two chimeric antibodies directed to human CD4 and one directed to the a-chain of the human interleukin-2 receptor [PDF]

, 1992
The general feasibility of chimerization of monoclonal antibodies (mAbs) has already been shown for a large number of them. In order to evaluate in vitro parameters relevant to immunosuppressive therapy, we have chimerized and synthesized two anti-CD4 ...
Flieger, Dimitri, Kaluzab, Brigitte, Lenz, Helmut, Reiter, Christian, Rieber, Ernst Peter, Riethmüller, Gert, Scheuer, Werner, Schwirzke, Marina, Weidle, Ulrich H., Weiss, Elisabeth H., Weissenhorn, Winfried   +10 more
core   +1 more source

Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer

Frontiers in Immunology, 2018
Adoptive cell therapy has emerged as a powerful treatment for advanced cancers resistant to conventional agents. Most notable are the remarkable responses seen in patients receiving autologous CD19-redirected chimeric antigen receptor (CAR) T cells for ...
Rohtesh S. Mehta, Katayoun Rezvani
doaj   +1 more source